 (JT Clin Pathol 1995;48:206-209) 
ea is 600 (y) and developed with p-nitrophenyl phosphate (5 1.g/ ow its 35% cut off ml; Sigma) in diethanolamine buffer for one hour in the dark. The reaction was stopped by the addition of 50 pl of 3 M sodium hydroxide.
The absorbance was measured at 405 nm (A405) s (before im-by a Multiscan ELISA plate reader (LabLs (that is, after systems). Two dilution curves (A405 v serum n samples were dilution) were plotted for each patient, one antibody con-with and the other without urea. The presence were collected of urea caused a leftward shift of the curve ponded to im-proportional to antibody avidity.'5 End point ml of PRP anti-titres (EPR) for each dilution curve were calconcentration culated at 35% of maximum absorbance and ity by this meth-the ratio of titres expressed as a percentage:
(titre (urea+)/titre (urea-)) x 100. All invere measured cubations and washes were carried out at room )sorbent assay temperature. ) measure avidFor comparative purposes samples were ob-.lique described tained from a small group of adult volunteers ibitol phosphate (n = 7) previously immunised with PRP-T. Agbarakwe, Gnffiths, Begg, Chapel 4% for both samples. Interplate variances of 12% (n= 13) and 14% (n = 13) were obtained.
COMPARISON OF ANTIBODY PROVOKED BY DIFFERENT VACCINES
There was no correlation between PRP concentration and avidity for any of the vaccines; correlation values (r) were 0 005 for HbOC vaccine, 0-025 for PRP-OMP vaccine and 0-004 for PRP-T vaccine. Nor were there significant differences between the median avidities or ranges obtained for each conjugate vaccine (fig 2) . All three vaccines elicited PRP antibodies of heterogeneous avidity. However, the avidity distribution pattern differed for each vaccine (fig 3) . The biphasic avidity distribution pattern elicited by HbOC ( fig 3A) suggests the presence of two antibody populations, one distributed about a mean of 43 (of relatively low avidity) and the other distributed about a mean of 73 (of relatively high avidity). A biphasic distribution is also seen in fig 3B but it is not as pronounced as in fig 3A. The low avidity population is distributed about a mean of 33 and the high avidity about a mean of 70. PRP-T elicits PRP antibodies which are distributed normally about a mean of 62. Adult serum samples showed a median high avidity of 80% (fig 2) . The FDA serum had an avidity of 65% as measured by this ELISA method. throughout this study. Intraplate variance was assessed by testing each sample several times (n =I1) in a single assay. The coefficient of variance (CV) was calculated and found to be Discussion These findings suggest that, after an accelerated series of conjugate Hib vaccine immunisation with either PRP-T, HbOC or PRP-OMP, the Hib specific IgG antibodies induced in five month old infants are heterogeneous with respect to avidity. No correlation was demonstrated between the type of vaccine preparation and median avidity though the range of avidities was much wider with two of the three vaccines. Avidity was also independant of antibody concentration. The latter finding confirming that the selection of serum samples with PRP IgG antibody levels greater than 0 5 jtg/ml was acceptable. The ability of a vaccine to protect an individual from disease has been attributed to an increase in antibody concentration. Even though all three conjugate vaccines elicit IgG PRP antibodies of a relatively high median avidity, each differs in the extent to which low avidity antibodies are induced. Low avidity antibodies are less efficient in their biological function than high avidity antibodies. 3 25 We found no correlation between antibody avidity and concentration, confirming that affinity is totally independant of PRP concentration. '2 22 The presence of high avidity PRP antibodies in the FDA standard correlates well with data presented recently by Hetherington and Rutkowski." Adult serum samples also possess high avidity PRP antibodies. It is possible therefore that the presence of small concentrations of maternal antibodies in the infants serum samples at two months of age may have contributed to the overall avidity. However, this is unlikely to be relevant in the post-immunisation samples taken at five months of age. We have demonstrated that avidity of PRP antibodies varies greatly from one infant's serum to another and is independent of vaccine preparation and antibody concentration. Our findings draw attention to antibody avidity which is an important factor in protection and needs to be considered when evaluating vaccine efficacy as the presence of a high concentration of PRP antibodies does not necessarily guarantee protection. 9 We are grateful for the assistance of the nursing staff involved in the Gloucester trial, for the cooperation of all the parents and children involved in that trial and to Dr R Booy for helpful discussions.
